



Spotlight on 2026 CPDD First and Co-Authored Posters & Presentations

Sunday, June 14 th	
Oral #9: Just Do It: Methods for Naloxone Distribution 2:15-3:15PM OCC, Level 1, Room B119	Co-Author: Jeffrey Samet <i>A Re-Aim Implementation Evaluation of Community Naloxone Distribution Strategies in the Massachusetts Healing Communities Study</i>
Poster Session 1 5:00 – 6:30PM OCC, Level 1, Exhibit Hall A	Co-Author: Jen Edelman S38 <i>Buprenorphine Dose and Time to Treatment Discontinuation Among U.S. Veterans With Opioid Use Disorder: A Target Trial Emulation</i>
	Co-Author: Ingrid Binswanger S49 <i>Consensus on Proms for Recovery-Oriented Oud Care: A Partner-Engaged Mixed-Methods Study</i>
Monday, June 15 th	
Oral #20: Climbing Mount Hood: Treatment Induction Methods for Individuals with Opioid Use Disorder 10:00 – 11:00AM OCC, Level 1, Room C123	Co-Author: Ned Nunes <i>First Dose Withdrawal Suppression With Injectable Weekly and Monthly Buprenorphine (CAM2038) and the Relationship Between Buprenorphine Plasma Concentrations and Withdrawal Suppression in Participants With Opioid Use Disorder</i>
	Co-Author: Anthony Spadaro <i>Safety of Rapid High-Dose Buprenorphine Initiation Among Fentanyl-Exposed Patients: A Pilot Sequential Cohort Study</i>
Poster Session 2 5:45 – 6:30PM OCC, Level 1, Exhibit Hall A	Co-Author: Jeffrey Samet M27 <i>Trajectory Analysis of Buprenorphine Treatment Episodes Based on Daily Buprenorphine Dosage and Associated Characteristics</i>
	Co-Author: Roger Weiss M50 <i>Satisfaction, Usability, and Engagement With the Healthy Women Digital Intervention for Women in Treatment for Opioid Use Disorder</i>
	Presenter: Megan Heeney M114 <i>An Assessment of Substance Use Frequency and Addiction Consults at a Level 1 Trauma Center</i>
	Co-Author: Vivian Tsang M124 <i>Exploring Patterns of Concurrent Substance use, Psychedelic Dosing and Intentions, and Childhood Trauma in Psychedelic Use in College Aged Adults</i>

	Co-Author: Anthony Spadaro M157 <i>Continuous Naloxone Infusions Are Associated With Prolonged Length of Stay Compared to Intermittent Naloxone Boluses: From the Toxic Fentanyl Study Group</i>
--	---

Tuesday, June 16 th	
Symposia 8:00 – 9:30AM OCC, Level 1, Room B114 Poster Session 3 5:30 – 7:00PM OCC, Level 1, Exhibit Hall A	Speaker: Will Garneau <i>Door to Balloon Time for Withdrawal: Evidence & New Approaches for Acute Withdrawal in the Fentanyl Era</i> Presenter: Jeffrey Samet T36 <i>Returning to Communities to Close the Feedback Loop on Community Approaches to End the Opioid Overdose Crisis in the Massachusetts Healing Communities Study (HCS)</i> Co-Author: Jeffrey Samet T68 <i>Social Norms of Recreational Cannabis Use After Its Decriminalization in Georgia: A Qualitative Study</i> Co-Author: Kathy Bradley T95 <i>Comparison of Brief Cannabis Measures for Identifying Risk of Cud</i>

Wednesday, June 17 th	
Poster Session 4 3:30 – 5:00PM OCC, Level 1, Exhibit Hall A	Co-Author: Jen Edelman W3 <i>Validity of Attention-Deficit/Hyperactivity Disorder Diagnoses in U.S. Veterans Health Administration Data: A Chart Verification Study</i> Co-Author: Jen Edelman W19 <i>Attitudes Towards Long-Acting Injectable HIV Pre-Exposure Prophylaxis (LAI Prep) Among People who Inject Drugs: The Roles of Medical Mistrust and Anticipated Stigma</i> Co-Author: Vivian Tsang W24 <i>Characterization of Psychiatric Comorbidities and Early Substance Use Outcomes Among Individuals Accessing Hospital-Based Withdrawal Management for a Substance Use Disorder - Findings From the Road to Recovery Cohort Study</i> Presenter: Patrick O'Connor; Co-Authors: Jeffrey Samet, Jen Edelman, Jules Canfield, Natalie Karter W29 <i>Research in Addiction Medicine Scholars (RAMS) Program for Addiction Fellows: A 10-Year Experience</i> Co-Author: Kristin Prewitt W55 <i>Slow Outpatient Taper of Buprenorphine Compared to Remaining on Maintenance Treatment During Pregnancy: A Cost-Effective Analysis</i> Presenter: Clarissa O'Connor; Co-Author: Claire Garpestad W83 <i>Differences in Uptake of Inpatient Long-Acting Injectable Buprenorphine Six Months After Implementation Across Three Hospitals</i>

	Co-Author: Clarissa O’Conor W84 <i>Implementation Barriers and Facilitators to Integrating Long-Acting Injectable Buprenorphine into Inpatient Addiction Care</i> Co-Author: Kathy Bradley W89 <i>Patient, Clinical, and Care-Delivery Factors Associated With Different Medication Treatments for Alcohol Withdrawal Syndrome in Hospitalized Patients</i> Co-Author: Ingrid Binswanger W107 <i>Health Insurance Transitions Following Health Plan Disenrollment Among Patients Receiving Medications for Opioid Use Disorder</i>
--	---